Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism

Crizotinib is a standard treatment for advanced ALK‐positive non‐small‐cell lung cancer (NSCLC). We undertook this study to investigate the pharmacokinetics of crizotinib and clinical and pharmacogenomic factors that may increase the risk of adverse events (AEs). We defined clinically significant AE...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Fujiwara, Yutaka, Hamada, Akinobu, Mizugaki, Hidenori, Aikawa, Hiroaki, Hata, Toshiyuki, Horinouchi, Hidehito, Kanda, Shintaro, Goto, Yasushi, Itahashi, Kota, Nokihara, Hiroshi, Yamamoto, Noboru, Ohe, Yuichiro
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2016
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4982581/
https://ncbi.nlm.nih.gov/pubmed/27270784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12983
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge